Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) announced multiple Ocaliva®(obeticholic acid) for PBC and INT-767 data presentations at the upcoming American Academy for the Study of Liver …
Intercept Pharmaceuticals Inc (NASDAQ:ICPT) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending …
Intercept Pharmaceuticals Inc (NASDAQ:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced …
In a research report released Friday, Cantor analyst Elemer Piros reiterated a Sell rating on shares of Intercept Pharmaceuticals Inc (NASDAQ:ICPT), with a price …
Both Relypsa Inc (NASDAQ:RLYP) and Intercept Pharmaceuticals Inc (NASDAQ:ICPT) received welcome news recently as a competing drug to Relypsa’s Veltassa encounters some difficulties …
Celator Pharmaceuticals Inc (NASDAQ:CPXX) is up an overwhelming 71% to $30.12 in pre-market trading following this morning’s announcement that the company will be …
Needham & Company analyst Alan Carr weighs in with a few insights on Intercept Pharmaceuticals Inc (NASDAQ:ICPT), after hosting a meeting with Doug Dieterich, MD and Alyson Harty, …
Facebook Inc Facebook Inc (NASDAQ:FB) has added some new features to its Facebook Live to give people “more ways to discover, share, and interact …
Merrill Lynch’s healthcare analyst Ying Huang weighed in on Intercept Pharmaceuticals Inc (NASDAQ:ICPT), after the FDA advisory committee unanimously recommended approval of the company’s liver drug. The …
